Compared to ER/PR positive BC, patients diagnosed with HER2-positive BC have a shorter survival median and tend to develop relapses; therefore, HER2 expression should be tested for in every case of BC [20,21,22]. This evidence concerns the gene ERBB2 and breast cancer.